Get the Stockscreener App
30.31
2.95%
-0.92
After Hours:
30.91
0.60
+1.98%
Ultragenyx Pharmaceutical Inc stock is traded at $30.31, with a volume of 1.39M.
It is down -2.95% in the last 24 hours and up +7.83% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$31.23
Open:
$31.02
24h Volume:
1.39M
Relative Volume:
0.73
Market Cap:
$2.92B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-4.6847
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
-4.75%
1M Performance:
+7.83%
6M Performance:
-24.77%
1Y Performance:
-47.59%
1-Day Range:
$30.27
$31.47
1-Week Range:
$30.27
$31.87
52-Week Range:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
30.31 | 3.02B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Alliancebernstein L.P. Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Reports Positive Phase 3 Gene Therapy Results - MSN
Ultragenyx Makes Bid for Dimension TherapeuticsBiotech Movers - TheStreet
Ultragenyx Pharmaceutical's (RARE) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Parkman Healthcare Partners LLC Purchases 204,085 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Fred Alger Management LLC - MarketBeat
121,510 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Cubist Systematic Strategies LLC - MarketBeat
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome - Zacks Investment Research
Ultragenyx releases long-term phase 3 data on gene therapy for metabolic disorder - MSN
Alyeska Investment Group L.P. Has $54.15 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Cinctive Capital Management LP Purchases 14,301 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 04 - MarketScreener
Ionis Rare Neurological Disease Candidate Receives FDA Breakthrough StatusIonis Pharmaceuticals (NASDAQ:IONS) - Benzinga
RARE Reports Positive Long-Term Data From Metabolic Disorder Study - sharewise.com
Ultragenyx stock maintains Buy rating at H.C. Wainwright on strong GSD1a data By Investing.com - Investing.com South Africa
Ultragenyx stock maintains Buy rating at H.C. Wainwright on strong GSD1a data - Investing.com
Ultragenyx reports positive long-term data for GSDIa gene therapy - Investing.com
Cutter Capital Management LP Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports positive long-term data for GSDIa gene therapy By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Reports Positive Phase 3 Data on Rare Metabolic Disorder Treatment - MarketScreener
Ultragenyx Pharmaceutical Inc. Reports Positive Phase 3 Results for DTX401 Gene Therapy in Glycogen Storage Disease Type Ia with Significant Reductions in Cornstarch Intake and Improved Glycemic Control - Quiver Quantitative
Ultragenyx Announces Positive Longer-term Data from Phase 3 - GlobeNewswire
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - Yahoo Finance
Ultragenyx SVP Huizenga sells $2.6k in shares - Investing.com
Will Ultragenyx Pharmaceutical Inc. Bounce From 52 Week LowJuly 2025 Drop Watch & Safe Capital Growth Stock Tips - beatles.ru
Ultragenyx Pharmaceutical Inc. Volume Confirms Breakout — Analysts Bullish2025 Bull vs Bear & Free AI Powered Buy and Sell Recommendations - beatles.ru
Adage Capital Partners GP L.L.C. Has $77.82 Million Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
5 Companies Caught on a Carousel of FDA Confusion - BioSpace
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 6.5%Time to Buy? - MarketBeat
Real time scanner hits for Ultragenyx Pharmaceutical Inc. explained2025 Top Gainers & Consistent Profit Alerts - Newser
Ultragenyx Pharmaceutical Inc. stock daily chart insightsShort Setup & Daily Risk Controlled Trade Plans - Newser
Vestal Point Capital LP Cuts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Institutional scanner results for Ultragenyx Pharmaceutical Inc.Market Sentiment Report & Entry Point Confirmation Alerts - Newser
Graham Capital Management L.P. Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
How to use Fibonacci retracement on Ultragenyx Pharmaceutical Inc.Weekly Trend Report & Fast Gain Stock Tips - Newser
Live market analysis of Ultragenyx Pharmaceutical Inc.Portfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
What machine learning models say about Ultragenyx Pharmaceutical Inc.July 2025 Market Mood & Verified Technical Trade Signals - Newser
B. Metzler seel. Sohn & Co. AG Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
What earnings revisions data tells us about Ultragenyx Pharmaceutical Inc.2025 Institutional Moves & AI Powered Market Trend Analysis - Newser
Is Ultragenyx Pharmaceutical Inc. stock a good pick for beginnersGap Up & Long-Term Growth Plans - خودرو بانک
Ultragenyx Pharmaceutical Inc. recovery potential after sell offWeekly Investment Report & Safe Entry Point Identification - Newser
Applying sector rotation models to Ultragenyx Pharmaceutical Inc.July 2025 Selloffs & Safe Capital Growth Tips - Newser
Real time pattern detection on Ultragenyx Pharmaceutical Inc. stock2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Rare Disease Therapy Approvals By FDA Speed Up Via New ProcessNeurogene (NASDAQ:NGNE) - Benzinga
Ultragenyx’s Strategic Momentum: A Rare Disease Biotech on the Cusp of Multiple Catalysts - AInvest
Ultragenyx's Strategic Momentum in Rare Disease Innovation and Commercialization - AInvest
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 10 - MarketScreener
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Weekly Risk Report & Entry Point Confirmation Signals - Newser
Long term hold vs stop loss in Ultragenyx Pharmaceutical Inc.Global Markets & Low Risk High Reward Trade Ideas - Newser
Driehaus Capital Management LLC Has $30.88 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):